TOPRA's One-Day Biotech Meeting
Understanding your biotech product? analytical and bio-analytical characterization.
Understanding Your Biotech Product-Analytical and Bio-analytical Characterization
Dates:
Wednesday
28th January 2009
Venue:
Radisson SAS
Portman Hotel
London, UK
Aims of the course
To ensure that delegates have the appropriate knowledge in the field of analytical and bioanalytical characterization to allow them to undertake their professional roles and specifically as follows:
• The techniques used to characterize biopharmaceutical medicinal products
• Regulatory requirements and expectations for characterisation data at different stages of the product development cycle
• Impact of process variables on product quality
• Requirements for comparability assessment following process changes
• Importance of characterisation techniques in a biosimilar product MAA.
Who should attend
The conference is designed for regulatory staff who are working with biotechnology-derived products, particularly those who may not have first hand manufacturing or process development experience, and those who are new to regulatory affairs. This conference would also be useful for anyone wishing to refresh his or her knowledge in the area.
Programme includes:
• Analytical characterisation concentrating on in vitro and biophysical techniques
• Bio-analytical techniques concentrating on bioassays and agency expectations for bioassays
• Impact of process variables on product quality
• Comparability assessment example following a major process change (a case study from Wyeth)
• Regulatory Agency perspective on comparability
• Biosimilars
Speakers include:
• Paul Chamberlain, Director, NDA Advisory Board, UK
• Brendan Fish, Director Bio-analytical Group, MedImmune, UK
• Brian Fitzpatrick, Associate Director of Analytical Development, Wyeth, Eire
• Stephen Fitzpatrick, Head of CMC RA, UCB Pharma Ltd, UK
• Kowid Ho, Biologicals/Biotechnology Unit, AFSSaPS, France
• Paul Jeffreys, Senior Manager RA, Eisai, UK
• Meg Leahey, Associate director, Wyeth Biotech, Eire
• Cecil Nick, Vice President, Parexel Consulting , UK
• Jane Robinson, NIBSC, UK
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
